蛋白质柱层析分离纯化验证现状1.docx

蛋白质柱层析分离纯化验证现状1.docx

  1. 1、本文档共23页,可阅读全部内容。
  2. 2、有哪些信誉好的足球投注网站(book118)网站文档一经付费(服务费),不意味着购买了该文档的版权,仅供个人/单位学习、研究之用,不得用于商业用途,未经授权,严禁复制、发行、汇编、翻译或者网络传播等,侵权必究。
  3. 3、本站所有内容均由合作方或网友上传,本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺!文档内容仅供研究参考,付费前请自行鉴别。如您付费,意味着您自己接受本站规则且自行承担风险,本站不退款、不进行额外附加服务;查看《如何避免下载的几个坑》。如果您已付费下载过本站文档,您可以点击 这里二次下载
  4. 4、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等,请点击“版权申诉”(推荐),也可以打举报电话:400-050-0827(电话支持时间:9:00-18:30)。
查看更多
Industry Perspective on the Validation of Column-Based Separation Processes for the Purification of Proteins蛋白质柱层析分离纯化验证现状Foreword前言The purpose of this document is to outline some of the significant issues related to the validation of columnbased separation processes used in the purification of proteins produced by recombinant DNA (rDNA), hybridoma technology, or peptide synthesis. While validation of these processes has been identified as a first priority by the PDA Biotechnology Task Force, the issues raised in certain sections of this document may have broader applications, including processes for non-protein pharmaceutical products purified by HPLC, as well as protein pharmaceuticals which are not produced by rDNA, hybridoma, or peptide synthesis technologies. 这个文件的目的是概述一些关于重组DNA(rDNA),杂交瘤技术,或多肽合成过程中有重大意义的柱分离纯化验证。当这些过程的验证已作为PDA生物技术工作团队的首要任务时,本文件中所提及的问题可能有更广泛的应用,包括利用高效液相色谱技术纯化非蛋白医药产品,又包括不通过rDNA,杂交瘤,或肽合成技术生产的蛋白质药品。While column-based separations are key purification techniques in the production of recombinant proteins and monoclonal antibodies, little has been written regarding the validation of these processes. In general, process validation is the assurance that product quality is derived from careful attention to a number of factors, including process design, selection and use of quality parts and materials, and control of the process through appropriate in-process and end-product testing. In May 1987, the Center for Drugs and Biologics and the Center for Devices and Radiological Health of the Food and Drug Administration published the Guideline on General Principles of Process Validation. While this guideline is useful, it does not include all of the specific elements required in the validation of a manufacturing process. Therefore, the PDA established the Biotechnology Task Force on Purification and Scale-up to develop a practical guide for the validation of column-based separations used in the manufacture of proteins intended for use as therapeutic or diagnos

文档评论(0)

xingyuxiaxiang + 关注
实名认证
内容提供者

该用户很懒,什么也没介绍

1亿VIP精品文档

相关文档